Evidence map›Paper›PMID 29216299›Full record

ArticlePloS one2017

Recombinant Vaccinia virus-coded interferon inhibitor B18R: Expression, refolding and a use in a mammalian expression system with a RNA-vector.

Yuriy G Kim, Aliya Zh Baltabekova, Erzhan E Zhiyenbay, Altynai S Aksambayeva, Zhadyra S Shagyrova, Rinat Khannanov, Erlan M Ramanculov, Alexandr V Shustov

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. The strategies and advances of mRNA translation booster.Asian journal of pharmaceutical sciences · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. ComparativeAIMS microbiology · 2023
    Article
  13. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.Current topics in microbiology and immunology · 2022
    Article
  14. mRNA-Based Reprogramming Under Xeno-Free and Feeder-Free Conditions.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuriy G KimNational Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Aliya Zh BaltabekovaNational Center for Biotechnology, Astana, Kazakhstan.
Erzhan E ZhiyenbayNational Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Altynai S AksambayevaNational Center for Biotechnology, Astana, Kazakhstan.
Zhadyra S ShagyrovaNational Center for Biotechnology, Astana, Kazakhstan.
Rinat KhannanovNational Center for Biotechnology, Astana, Kazakhstan.
Erlan M RamanculovNational Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Alexandr V ShustovNational Center for Biotechnology, Astana, Kazakhstan.ORCID http://orcid.org/0000-0001-9880-9382
National Center for Biotechnology · KZNazarbayev University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B18R protein of Vaccinia virus binds to type I interferons and inhibits activation of interferon-mediated signal transduction. Cells which have unimpaired interferon signaling such as primary cell cultures or some industrially important cell lines are capable of development of an antiviral state. An establishment of the antiviral state limits replication of RNA-viruses and can suppress replication of RNA vectors. The interferon inhibitor B18R effectively prevents the establishment of the antiviral state. For this reason, B18R has become a ubiquitous component of protocols for epigenetic reprogramming which use transfections of RNA replicons or mRNA. Despite wide practical applicability, commercially available B18R is predominantly produced in cell cultures and little information has been published on a production and use of bacterially expressed B18R. Objectives of this study were to produce B18R in an E.coli expression system and to confirm the product's biological activity by using it to maintain RNA-vectors in cell cultures capable of the antiviral state. The described method allows the expression and efficient refolding to obtain 10-100 mg of B18R from a small-scale culture and the production process is economically attractive compared to a use of an eukaryotic expression. To check for a presence of the biological activity of bacterially-expressed B18R the protein was used to support persistence of an autonomously replicating RNA-vector in a cell culture which is capable of the antiviral state. A RNA-containing virus, Venezuelan equine encephalitis virus (VEE) can serve as an efficient vector for heterologous expression in cell cultures, although its replication is sensitive to the effects of type I interferons which limit a range of cell lines for a use with this vector. The VEE replicon was utilized to direct an expression of recombinant human granulocyte colony stimulating factor (G-CSF). The producing replicon could persist in HEK293 cells for sufficiently long time only in presence of B18R, whereas addition of B18R not only allowed persistence of the replicon but also increased production from the replicon. A model product granulocyte colony stimulating factor accumulated to 35.5 μg/ml during a 7 day experiment. This work describes efficacious expression and refolding of the viral cytokine inhibitor and demonstrates a utility of bacterially-expressed B18R.

Indexed as

Genetic VectorsChromatography, GelElectrophoresis, Polyacrylamide GelHEK293 CellsHumansProtein FoldingRecombinant ProteinsRNA, ViralVaccinia virusViral ProteinsB18R protein, Vaccinia virusRecombinant ProteinsRNA, ViralViral Proteins

Identifiers

PMID29216299
PMCPMC5720773
OpenAlexW2771425514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.